The nitric oxide prodrug V-PROLI/NO inhibits cellular uptake of proline

ACS Medicinal Chemistry Letters

Volumn 1, Issue 8, 2010, Pages 386-389

  Hong, Sam Y ^a   Borchert, Gregory L ^b   MacIag, Anna E ^b   Nandurdikar, Rahul S ^a   Saavedra, Joseph E ^b   Keefer, Larry K ^a   Phang, James M ^c   Chakrapani, Harinath ^d  

^a Laboratory of Comparative Carcinogenesis   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH   (India)

Author keywords

Nitric oxide; prodrug; PROLI NO; proline; transporter; V PROLI NO

Indexed keywords

CYTOCHROME P450; GLYCOLALDEHYDE DEHYDROGENASE; NITRIC OXIDE; NITRITE; PRODRUG; PROLINE; PROLINE DERIVATIVE;

ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; DRUG METABOLISM; DRUG PENETRATION; PERMEABILITY; PRIORITY JOURNAL;

EID: 78649308089     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml1000905     Document Type: Article

References (43)

1. Smith, D. J.; Chakravarthy, D.; Pulfer, S.; Simmons, M. L.; Hrabie, J. A.; Citro, M. L.; Saavedra, J. E.; Davies, K. M.; Hutsell, T. C.; Mooradian, D. L.; Hanson, S. R.; Keefer, L. K. Nitric oxide-releasing polymers containing the [N(O)NO]- group J. Med. Chem. 1996, 39, 1148-1156
2. Hrabie, J. A.; Keefer, L. K. Chemistry of the Nitric Oxide-Releasing Diazeniumdiolate ("Nitrosohydroxylamine") Functional Group and Its Oxygen-Substituted Derivatives Chem. Rev. 2002, 102, 1135-1154
3. 2-substituted diazeniumdiolates Free Radical Biol. Med. 2004, 37, 745-752
4. Scatena, R.; Bottoni, P.; Martorana, G. E.; Giardina, B. Nitric oxide donor drugs: an update on pathophysiology and therapeutic potential Expert Opin. Invest. Drugs 2005, 14, 835-846
5. Keefer, L. K. Nitric Oxide (NO)- and Nitroxyl (HNO)-Generating Diazeniumdiolates (NONOates): Emerging Commercial Opportunities Curr. Top. Med. Chem. 2005, 5, 625-636
6. Frost, M. C.; Reynolds, M. M.; Meyerhoff, M. E. Polymers incorporating nitric oxide releasing/generating substances for improved biocompatibility of blood-contacting medical devices Biomaterials 2005, 26, 1685-1693
7. Thatcher, G. R. An Introduction to NO-related Therapeutic Agents Curr. Top. Med. Chem. 2005, 5, 597-601
8. Stasko, N. A.; Schoenfisch, M. H. Dendrimers as a scaffold for nitric oxide release J. Am. Chem. Soc. 2006, 128, 8265-8271
9. Saavedra, J. E.; Billiar, T. R.; Williams, D. L.; Kim, Y.; Watkins, S. C.; Keefer, L. K. Targeting Nitric Oxide (NO) Delivery in Vivo. Design of a Liver-Selective NO Donor Prodrug That Blocks Tumor Necrosis Factor-a-Induced Apoptosis and Toxicity in the Liver J. Med. Chem. 1997, 40, 1947-1954
10. Kim, Y.; Kim, T.; Chung, H.; Talanian, R. V.; Yin, X.; Billiar, T. R. Nitric oxide prevents tumor necrosis factor α-induced rat hepatocyte apoptosis by the interruption of mitochondrial apoptotic signaling through S-nitrosylation of caspase-8 Hepatology 2000, 32, 770-778
11. Ricciardi, R.; Foley, D. P.; Quarfordt, S. H.; Saavedra, J. E.; Keefer, L. K.; Wheeler, S. M.; Donohue, S. E.; Callery, M. P.; Meyers, W. C. V-PYRRO/NO: an hepato-selective nitric oxide donor improves porcine liver hemodynamics and function after ischemia reperfusion Transplantation 2001, 71, 193-198
12. Shokolenko, I.; Oberyszyn, T. M.; D'Ambrosio, S. M.; Saavedra, J. E.; Keefer, L. K.; LeDoux, S. P.; Wilson, G. L.; Robertson, F. M. Protection of Human Keratinocyte mtDNA by Low-Level Nitric Oxide Nitric Oxide Biol. Chem. 2001, 5, 555-560
13. Liu, J.; Saavedra, J. E.; Lu, T.; Song, J.; Clark, J.; Waalkes, M. P.; Keefer, L. K. O 2-Vinyl 1-(Pyrrolidin-1-yl)diazen-1-ium-1,2-diolate Protection Againstd-Galactosamine/Endotoxin-Induced Hepatotoxicity in Mice: Genomic Analysis Using Microarrays J. Pharmacol. Exp. Ther. 2002, 300, 18-25
14. Stinson, S. F.; House, T.; Bramhall, C.; Saavedra, J. E.; Keefer, L. K.; Nims, R. W. Plasma pharmacokinetics of a liver-selective nitric oxide-donating diazeniumdiolate in the male C57BL/6 mouse Xenobiotica 2002, 32, 339-347
15. Li, C.; Liu, J.; Saavedra, J. E.; Keefer, L. K.; Waalkes, M. P. The nitric oxide donor, V-PYRRO/NO, protects against acetaminophen-induced nephrotoxicity in mice Toxicology 2003, 189, 173-180 (Pubitemid 36773853)
16. Liu, J.; Li, C.; Waalkes, M. P.; Clark, J.; Myers, P.; Saavedra, J. E.; Keefer, L. K. The nitric oxide donor, V-PYRRO/NO, protects against acetaminophen-induced hepatotoxicity in mice Hepatology 2003, 37, 324-333 (Pubitemid 36152531)
17. 2-Vinyl 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (V-PYRRO/NO) Protects HepG2 Cells against Cytochrome P450 2E1-Dependent Toxicity Mol. Pharmacol. 2004, 65, 130-138
18. 2-Vinyl 1-(Pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (V-PYRRO/NO), Protects against Cadmium-Induced Hepatotoxicity in Mice J. Pharmacol. Exp. Ther. 2004, 310, 18-24
19. Balogh, G. T.; Dalmadi, B.; Bielik, A.; Keseru, G. M. Identification of Nitric Oxide Donors by Biomimetic HTS Application Comb. Chem. High Throughput Screening 2005, 8, 347-352
20. Liu, J.; He, Y.; Chignell, C. F.; Clark, J.; Myers, P.; Saavedra, J. E.; Waalkes, M. P. Limited protective role of V-PYRRO/NO against cholestasis produced by alpha-naphthylisothiocyanate in mice Biochem. Pharmacol. 2005, 70, 144-151
21. Liu, J.; Waalkes, M. P. Nitric oxide and chemically induced hepatotoxicity: beneficial effects of the liver-selective nitric oxide donor, V-PYRRO/NO Toxicology 2005, 208, 289-297
22. Qu, W.; Liu, J.; Fuquay, R.; Shimoda, R.; Sakurai, T.; Saavedra, J. E.; Keefer, L. K.; Waalkes, M. P. The nitric oxide prodrug, V-PYRRO/NO, protects against cadmium toxicity and apoptosis at the cellular level Nitric Oxide Biol. Chem. 2005, 12, 114-120
23. Inami, K.; Nims, R. W.; Srinivasan, A.; Citro, M. L.; Saavedra, J. E.; Cederbaum, A. I.; Keefer, L. K. Metabolism of a liver-selective nitric oxide-releasing agent, V-PYRRO/NO, by human microsomal cytochromes P450 Nitric Oxide Biol. Chem. 2006, 14, 309-315
24. Qu, W.; Liu, J.; Fuquay, R.; Saavedra, J. E.; Keefer, L. K.; Waalkes, M. P. The nitric oxide prodrug, V-PYRRO/NO, mitigates arsenic-induced liver cell toxicity and apoptosis Cancer Lett. 2007, 256, 238-245
25. Edwards, C.; Feng, H.; Reynolds, C.; Mao, L.; Rockey, D. C. Effect of the nitric oxide donor V-PYRRO/NO on portal pressure and sinusoidal dynamics in normal and cirrhotic mice Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 294, G1311-G1317
26. Hong, S. Y.; Saavedra, J. E.; Keefer, L. K.; Chakrapani, H. Improved synthesis of V-PYRRO/NO, a liver-selective nitric oxide prodrug, and analogues Tetrahedron Lett. 2009, 50, 2069-2071
27. Chakrapani, H.; Showalter, B. M.; Kong, L.; Keefer, L. K.; Saavedra, J. E. V-PROLI/NO, a Prodrug of the Nitric Oxide Donor, PROLI/NO Org. Lett. 2007, 9, 3409-3412
28. Qu, W.; Liu, J.; Dill, A. L.; Saavedra, J. E.; Keefer, L. K.; Waalkes, M. P. V-PROLI/NO, a nitric oxide donor prodrug, protects liver cells from arsenic-induced toxicity Cancer Sci. 2009, 100, 382-388
29. Kojima, H.; Urano, Y.; Kikuchi, K.; Higuchi, T.; Hirata, Y.; Nagano, T. Fluorescent Indicators for Imaging Nitric Oxide Production Angew. Chem., Int. Ed. 1999, 38, 3209-3212
30. Wardman, P. Fluorescent and luminescent probes for measurement of oxidative and nitrosative species in cells and tissues: Progress, pitfalls, and prospects Free Radical Biol. Med. 2007, 43, 995-1022
31. Gong, P.; Cederbaum, A. I.; Nieto, N. The liver-selective nitric oxide donor O2-vinyl 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (V-PYRRO/NO) protects HepG2 cells against cytochrome P450 2E1-dependent toxicity Mol. Pharmacol. 2004, 65, 130-138
32. Chakrapani, H.; Maciag, A. E.; Citro, M. L.; Keefer, L. K.; Saavedra, J. E. Cell-Permeable Esters of Diazeniumdiolate-Based Nitric Oxide Prodrugs Org. Lett. 2008, 10, 5155-5158
33. Hong, S. Y.; Nandurdikar, R. S.; Keefer, L. K.; Saavedra, J. E.; Chakrapani, H. An improved synthesis of V-PROLI/NO, a cytochrome P450-activated nitric oxide prodrug Tetrahedron Lett. 2009, 50, 4545-4548
34. Herrera-Ruiz, D.; Knipp, G. T. Current perspectives on established and putative mammalian oligopeptide transporters J. Pharm. Sci. 2003, 92, 691-714
35. Daniel, H. Molecular and Integrative Physiology of Intestinal Peptide Transport Annu. Rev. Physiol. 2004, 66, 361-384 (Pubitemid 40614448)
36. Brandsch, M. Transport of L-proline, L-proline-containing peptides and related drugs at mammalian epithelial cell membranes Amino Acids 2006, 31, 119-136
37. Bröer, S. Amino Acid Transport Across Mammalian Intestinal and Renal Epithelia Physiol. Rev. 2008, 88, 249-286
38. Bröer, S. Apical Transporters for Neutral Amino Acids: Physiology and Pathophysiology Physiology 2008, 23, 95-103
39. Brandsch, M.; Knütter, I.; Bosse-Doenecke, E. Pharmaceutical and pharmacological importance of peptide transporters J. Pharm. Pharmacol. 2008, 60, 543-585
40. Metzner, L.; Neubert, K.; Brandsch, M. Substrate specificity of the amino acid transporter PAT1 Amino Acids 2006, 31, 111-117
41. The half-lives of PYRRO/NO and PROLI/NO are 3 and 1.8 s, respectively, (9, 43) and are expected to be completely decomposed during 1 h. SARCO/NO is expected to have a half-life comparable to PYRRO/NO and PROLI/NO and should completely decompose within 1 h.
42. Nitric Oxide Analyzer NOA 280i Operation and Maintenance Manual, Version 3.0; Sievers Instruments, Inc.: Boulder, CO, 2000.
43. Saavedra, J. E.; Southan, G. J.; Davies, K. M.; Lundell, A.; Markou, C.; Hanson, S. R.; Adrie, C.; Hurford, W. E.; Zapol, W. M.; Keefer, L. K. Localizing antithrombotic and vasodilatory activity with a novel, ultrafast nitric oxide donor J. Med. Chem. 1996, 39, 4361-4365